As Russia became the first nation in the world to successfully register a novel coronavirus vaccine in the world, nearly eight months after the pandemic started to spread, as many as 20 countries, including India, Saudi Arabia, Brazil, Philippines and South Korea have expressed interest to procure doses of the Russian vaccine as well as conduct large-scale trials going forward, even though the vaccine's launch has been excessively marred by controversies- from its usage, effectiveness and safety.
Russia Development Investment Fund or RDIF, which is financing the work on the vaccine has expressed interest to conduct large scale trials of the same in countries outside Russia and enter into strategic partnerships, which can include India as well, making it easier for the Indian population to get their hands on the vaccine.
India's production facility could help the Russian vaccine move forward by striking a deal with the Russian government to conduct phase II and III of the vaccine trials in the country, which is also a necessary requirement for any vaccine to be made available globally. Trials conducted this way will also help in ruling out any side-effects, test efficacy and weigh the pros and cons in a varied section of the population, something which has so far been missing with the Russian trials, and for which India appears to be well-equipped.
Moreover, since India is also one of the leading vaccine manufacturer, the deal could doubly benefit the Russian authorities in ramping up production - so it could be a win-win situation for both India and Russia. What are your views?






